Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (887)	9/3/1999 11:57:00 AM
From: yosi s	Respond to of 1386

When all is said and done. Pharmos came out with a good safe products, ie, Lotemax and Alrex. I just wished they could speed up Le Tobra . and move on with NDA and added on sales outside US. At least market shares is picking up in certain regions of US. Lets see if target for profitability remain on target.

To: Dr. John M. de Castro who wrote (887)	9/4/1999 8:45:00 PM
From: arnie h	Read Replies (1) \| Respond to of 1386

Dr John: <Preoperative and postoperative medications used for cataract surgery.> Thanks for calling this review to my attention. I had seen something on this earlier in the year and it certainly seemed like another good arrow in the quiver. I've not seen any PARS revenues attached to this indication but it would seem to be a useful and important application. Are you or anyone else on the thread aware of the use of LE for cataract surgery? Also, whether further FDA approval is required? Arnie